Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren’s syndrome

OBJECTIVES: To evaluate humoral and cellular immune responses and adverse events (AEs) after COVID-19 vaccination in patients with primary Sjögren’s syndrome (pSS) compared to healthy controls (HC), and disease activity following vaccination in patients with pSS. METHODS: 67 patients with pSS and 33...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstappen, Gwenny M, de Wolff, Liseth, Arends, Suzanne, Heiermann, Hella-Marie, van Sleen, Yannick, Visser, Annie, Terpstra, Janneke H, Diavatopoulos, Dimitri A, van der Heiden, Marieke, Vissink, Arjan, van Baarle, Debbie, Kroese, Frans G M, Bootsma, Hendrika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Sjögren Syndrome
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006196/
https://www.ncbi.nlm.nih.gov/pubmed/35414631
http://dx.doi.org/10.1136/rmdopen-2022-002265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006196/
https://www.ncbi.nlm.nih.gov/pubmed/35414631
http://dx.doi.org/10.1136/rmdopen-2022-002265

Ejemplares similares